Back to Results
First PageMeta Content
Oncology / Phosphoinositide 3-kinase / Protein kinases / AKT / P110α / Gefitinib / Epidermal growth factor receptor / PI3 / Tyrosine kinase / Medicine / Chemistry / Organic chemistry


BACR Interview #4: Professor Paul Workman (Piramed Pharma / Chroma Therapeutics) In the fourth of our series of interviews with BACR members
Add to Reading List

Document Date: 2009-02-13 05:08:30

Open Document

File Size: 100,33 KB

Share Result on Facebook

Company

JP Morgan / Yamanouchi Pharma / Chroma Therapeutics / AstraZeneca / Piramed Pharma / Roche / Genentech / Beremans Ltd / /

Country

United Kingdom / /

Currency

USD / /

Event

FDA Phase / M&A / /

Facility

The Institute / /

IndustryTerm

excellent management / kinase inhibitor technology / biotechnology / chemical biology studies / cancer therapy / large pharmaceutical / Cancer Therapeutics / chemical inhibitors / treatment of a serious disease / /

MedicalCondition

cancers / ovarian cancer / strokes / cancer / glioma cells / different cancers / serious life-threatening disease / serious disease / glioma / individual cancers / stroke / tumour / target cancer / brain tumours / diabetes / gliomas / diseases / lung and breast cancer / then stroke / hormone-refractory prostate cancer / /

MedicalTreatment

cancer therapy / /

Organization

BACR / Cancer Research UK Centre for Cancer Therapeutics / Institute for Cancer Research / Sutton and Harrap / /

Person

Michael Waterfield / Peter Parker / Paul Workman / Nick Miller / /

Position

Professor / Director / Workman / Professor of Pharmacology and Therapeutics there / /

Product

PI3 / Herceptin / Gleevec / Iressa / Erbitux / Sutent / Tarceva / /

PublishedMedium

Cancer Research / /

Technology

drug discovery / biotechnology / treating cancer / PI3 kinase inhibitor technology / drug development / human genome / apoptosis / /

URL

www.beremans.com / /

SocialTag